You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Litigation Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)


✉ Email this page to a colleague

« Back to Dashboard


CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)

Docket ⤷  Try a Trial Date Filed 2017-09-06
Court District Court, D. New Jersey Date Terminated 2019-09-05
Cause 15:1126 Patent Infringement Assigned To Susan Davis Wigenton
Jury Demand None Referred To Leda D. Wettre
Parties ALVOGEN PINE BROOK, LLC; CELGENE CORPORATION; HON. GARRETT E. BROWN, JR.; LOTUS PHARMACEUTICAL CO., LTD.
Patents 6,045,501; 6,315,720; 6,561,977; 6,755,784; 7,189,740; 7,465,800; 7,765,106; 7,765,107; 7,855,217; 7,895,059; 7,968,569; 8,112,290; 8,315,886; 8,404,717; 8,457,988; 8,530,498; 8,589,182; 8,626,531; 8,645,160; 8,648,095; 8,731,963; 9,056,120; 9,101,621; 9,101,622
Attorneys AARON SCOTT ECKENTHAL; BRIAN JOHN FORSATZ; CHARLES MICHAEL LIZZA; DAVID LEIGH MOSES; FRANK CHARLES CALVOSA; GARRETT E. BROWN , JR.; SARAH ANN SULLIVAN; TEDD WILLIAM VAN BUSKIRK; WILLIAM C. BATON; WILLIAM L. MENTLIK
Firms Jams; Lerner David Littenberg Krumholz and Mentlik LLP; Lerner, David, Littenberg, Krumholz & Mentlik, LLP; Quinn Emanuel Uquhart & Sullival LLP; Quinn Emanuel Urquhart & Sullivan LLC; Saul Ewing Arnstein & Lehr LLP
Link to Docket External link to docket
Small Molecule Drugs cited in CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.
The small molecule drugs covered by the patents cited in this case are ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , and ⤷  Try a Trial .
Biologic Drugs cited in CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.
The biologic drugs covered by the patents cited in this case are ⤷  Try a Trial and ⤷  Try a Trial .

Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-09-06 1 expiration of United States Patent Nos. 5,635,517 (“the ʼ517 patent”); 6,315,720 (“the ʼ720 … 35 PageID: 2 patent”); 6,561,977 (“the ʼ977 patent”); 6,755,784 (“the ʼ784 patent”); 7,189,740 (“the…“the ʼ740 patent”); 7,465,800 (“the ʼ800 patent”); 7,855,217 (“the ʼ217 patent”); 7,968,569 (“the ʼ569…ʼ569 patent”); 8,315,886 (“the ʼ886 patent”); 8,404,717 (“the ʼ717 patent”); 8,530,498 (“the ʼ498 patent…,531 (“the ʼ531 patent”); 8,648,095 (“the ʼ095 patent”); 9,056,120 (“the ʼ120 patent”); 9,101,621 (“the External link to document
2019-01-30 101 Covenant Not to Sue for Infringement of U.S. Patent No. 7,855,217 (Attachments: # 1 Certificate of Service… 5 September 2019 2:17-cv-06842 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2019-02-21 105 BIFURCATION AND STAY WITH RESPECT TO U.S. PATENT NOS. 6,315,720, 6,561,977, 6,775,784, 8,315,886 AND 8,626,531… 5 September 2019 2:17-cv-06842 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2019-03-29 109 Judgment, the term Patents-in-Suit shall mean U.S. Patent Nos. 5.635,517; 6,3 15,720; 6,561,977; 6,755,784; …the term “Patents—in—Suit” shall mean U.S. Patent Nos. 5.635,517; 6,3 15,720; 6,561,977; 6,755,784… 4. Until expiration of the Patents.ineSuit, Lotus, including any of Its successors…parties in connection with any infringement of the Patents-in-Suit by any such third panics in connection…C.F.R. § 31 4.94(a)( 12) with respect to the Patents-in-Suit. 9. Nothing External link to document
2018-06-21 69 disclose prior art U.S. Patent No. 6,045,501, which according to the REMS Patents: [P]rovides…the “REMS Patents”1) ____ fall precisely within this category. These patents claim the patent-ineligible…the REMS Patents are listed as an inventor on any other asserted patents, and the REMS Patents have distinct…’886 Patent Is Invalid For Claiming A Patent-Ineligible Abstract Idea The ’886 Patent is also… B. The Drug Delivery Patents Are Invalid For Claiming A Patent-Ineligible External link to document
2018-08-08 81 Statement , and interest in United States Patent No. 7,855,217 (“the ’217 patent”). Celgene hereby agrees… FOR INFRINGEMENT OF U.S. PATENT NO. 7,855,217 Case 2:17-cv-06842-SDW-LDW Document 81 Filed…successors in interest, for infringement of the ’217 patent based on the filing of Abbreviated New Drug Application…covenant, Celgene does not concede that the ’217 patent is not infringed, is invalid, or is unenforceable… 5 September 2019 2:17-cv-06842 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2018-09-07 82 Pat. No. 8,645,160 (Entereg); U.S. Pat. No. 7,765,106 (Xyrem); U.S. Pat. No. 7,765,107 (Xyrem); U.S.… Lotus’s reasoning, every method-of-use patent would be patent-ineligible because it can be reduced … by their own patents. Under Lotus’s theory, however, those other REMS and REMS patents would cover …s REMS Patents were directed to an abstract idea (which Celgene disputes), they remain patent eligible…that a patent infringement suit can be dismissed at the pleading stage for lack of patentable subject External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.